pCR8

BALB/c (female, 6 weeks old, subcutaneously injected with 5×10⁵ 4T1 cells)^[1]

10 mg/kg (monotherapy); 10 mg/kg (combination with aPD-L1)

i.v.; every 2 days; 8 days; i.p. (aPD-L1, every 3 days; 8 days)

Suppressed tumor growth, with reduced tumor weight and volume compared to the PBS group.
Decreased CCNK and CDK12 expression in tumor tissues relative to the PBS group.
Increased the percentage of CD8⁺ T cells in tumor tissues compared to the PBS group.
Produced the most significant tumor suppression when combined with aPD-L1, with average tumor volume less than 50 mm³ after treatment.
Showed the highest levels of CD8⁺ T cells and GzmB⁺ CD8⁺ T cells in blood, tumor, and spleen tissues when combined with aPD-L1.
Upregulated IL-6, IL-12, IFN-γ, and TNF-α in tumor tissues to the greatest extent when combined with aPD-L1.
Maintained stable body weights, with no significant differences in white blood cell count, red blood cell count, hemoglobin, or platelet count compared to the PBS group.
Showed normal liver and kidney function markers (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, urea nitrogen, creatinine) with no significant tissue damage in heart, liver, spleen, lung, or kidney.